BR112013002375A2 - composto, composição farmacêutica, métodos de tratar um indivíduo para um distúrbio proliferativo de induzir a apoptose das células cancerígenas, e de inibir a atividade de cinase em um mamífero, e, processo de preparação de composto - Google Patents
composto, composição farmacêutica, métodos de tratar um indivíduo para um distúrbio proliferativo de induzir a apoptose das células cancerígenas, e de inibir a atividade de cinase em um mamífero, e, processo de preparação de compostoInfo
- Publication number
- BR112013002375A2 BR112013002375A2 BR112013002375A BR112013002375A BR112013002375A2 BR 112013002375 A2 BR112013002375 A2 BR 112013002375A2 BR 112013002375 A BR112013002375 A BR 112013002375A BR 112013002375 A BR112013002375 A BR 112013002375A BR 112013002375 A2 BR112013002375 A2 BR 112013002375A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- methods
- mammal
- treating
- individual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
composto, composição farmacêutica, métodos de tratar um indivíduo para um distúrbio proliferativo de induzir a apoptose das células cancerígenas, e de inibir a atividade de cinase em um mamífero, e, processo de preparação de composto. os compostos de acordo com a fórmula (i) bem como sais destes: em que r^ 1^ e r^ 2^ são como definidos neste, são úteis como agentes antiproliferativos e inibidores de cinase. os métodos sintéticos para a preparação dos compostos da fórmula (i) também são fornecidos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37094610P | 2010-08-05 | 2010-08-05 | |
US61/370946 | 2010-08-05 | ||
PCT/US2011/044807 WO2012018540A1 (en) | 2010-08-05 | 2011-07-21 | 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidine-6-carbonitriles and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013002375A2 true BR112013002375A2 (pt) | 2016-05-24 |
BR112013002375B1 BR112013002375B1 (pt) | 2020-05-12 |
Family
ID=45559737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013002375-9A BR112013002375B1 (pt) | 2010-08-05 | 2011-07-21 | Composto, processo de preparação do mesmo, composição farmacêutica, e, usos de um composto |
Country Status (17)
Country | Link |
---|---|
US (1) | US8987267B2 (pt) |
EP (1) | EP2600719B1 (pt) |
JP (1) | JP5512894B2 (pt) |
KR (1) | KR101434841B1 (pt) |
CN (1) | CN103200822B (pt) |
AU (1) | AU2011286282B2 (pt) |
BR (1) | BR112013002375B1 (pt) |
CA (1) | CA2807498C (pt) |
DK (1) | DK2600719T3 (pt) |
EA (1) | EA022527B1 (pt) |
ES (1) | ES2525866T3 (pt) |
IL (1) | IL224555A (pt) |
MX (1) | MX2013001427A (pt) |
NZ (1) | NZ606281A (pt) |
PL (1) | PL2600719T3 (pt) |
PT (1) | PT2600719E (pt) |
WO (1) | WO2012018540A1 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2807498C (en) * | 2010-08-05 | 2017-02-07 | Temple University-Of The Commonwealth System Of Higher Education | 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof |
WO2014031571A1 (en) * | 2012-08-21 | 2014-02-27 | Icahn School Of Medicine At Mount Sinai | Treatment of viral infections |
EP3733184B1 (en) | 2013-03-14 | 2023-08-30 | Icahn School of Medicine at Mount Sinai | Pyrimidine compounds for use in the treatment of cancer |
CN106659765B (zh) | 2014-04-04 | 2021-08-13 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
JP6631616B2 (ja) | 2014-07-26 | 2020-01-15 | ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド | CDK阻害剤としての2−アミノ−ピリド[2,3−d]ピリミジン−7(8H)−オン誘導体及びその使用 |
CN104447739B (zh) * | 2014-11-07 | 2016-02-17 | 郑州泰基鸿诺药物科技有限公司 | 一种氘代Palbociclib衍生物、制备方法及应用 |
CN104447743B (zh) * | 2014-11-26 | 2016-03-02 | 苏州明锐医药科技有限公司 | 帕博西尼的制备方法 |
CN104496983B (zh) | 2014-11-26 | 2016-06-08 | 苏州明锐医药科技有限公司 | 一种帕博西尼的制备方法 |
CN104478874B (zh) * | 2014-12-08 | 2016-03-02 | 新发药业有限公司 | 一种帕博赛布的制备方法 |
CN104610254B (zh) * | 2015-01-26 | 2017-02-01 | 新发药业有限公司 | 一种帕博赛布的低成本制备方法 |
CN105111205B (zh) * | 2015-09-12 | 2017-01-04 | 山东罗欣药业集团股份有限公司 | 一种帕博西尼的制备方法 |
RU2747311C2 (ru) | 2016-12-16 | 2021-05-04 | СиСТОУН ФАРМАСЬЮТИКАЛС (СУЧЖОУ) КО., ЛТД. | Ингибитор CDK4/6 |
JP2021514359A (ja) | 2018-02-15 | 2021-06-10 | ニューベイション・バイオ・インコーポレイテッドNuvation Bio Inc. | キナーゼ阻害剤としての複素環式化合物 |
KR102286701B1 (ko) * | 2018-09-28 | 2021-08-06 | 재단법인 대구경북첨단의료산업진흥재단 | 피리도[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
JP7378167B2 (ja) * | 2018-11-12 | 2023-11-13 | オンコノバ セラピューティクス インコーポレイテッド | 8‐シクロペンチル‐7‐オキソ‐2‐(4‐ピペラジン‐1‐イル‐フェニルアミノ)‐7,8‐ジヒドロ‐ピリド[2,3‐d]ピリミジン‐6‐カルボニトリル及び同化合物の増殖性障害の治療における使用 |
TWI818930B (zh) * | 2018-11-12 | 2023-10-21 | 美商昂可諾法治療股份有限公司 | 8-環戊基-7-側氧基-2-(4-哌嗪-1-基-苯基胺基)-7,8-二氫-吡啶[2,3-d]嘧啶-6-氰基及其用於治療增生性疾病的用途 |
US20220220103A1 (en) * | 2018-12-28 | 2022-07-14 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
EP3902801A4 (en) * | 2018-12-28 | 2022-12-14 | SPV Therapeutics Inc. | CYCLINE-DEPENDENT KINASE INHIBITORS |
CA3145821A1 (en) * | 2019-07-02 | 2021-01-07 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
EP4065578A1 (en) | 2019-11-26 | 2022-10-05 | Theravance Biopharma R&D IP, LLC | Fused pyrimidine pyridinone compounds as jak inhibitors |
WO2021242770A1 (en) * | 2020-05-28 | 2021-12-02 | University Of Washington | Drug-like molecules and methods for the therapeutic targeting of viral rna structures |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
WO2023091724A1 (en) * | 2021-11-18 | 2023-05-25 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
WO2023092104A1 (en) * | 2021-11-18 | 2023-05-25 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
WO2023230288A1 (en) * | 2022-05-25 | 2023-11-30 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5620981A (en) | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
ID27589A (id) * | 1998-05-26 | 2001-04-12 | Warner Lambert Comapny | Pirimidina bisiklik dan dihidropirimidina bisiklik 3,4 sebagai penghambat proliferasi selular |
CZ20022521A3 (cs) * | 2000-01-27 | 2003-02-12 | Warner-Lambert Company | Pyridopyrimidinonové deriváty pro léčení neurodegenerativních onemocnění |
BR0108611A (pt) | 2000-02-25 | 2003-05-06 | Hoffmann La Roche | Moduladores de receptor de adenosina |
IL151480A0 (en) | 2000-03-06 | 2003-04-10 | Warner Lambert Co | 5-alkylpyrido[2,3-d] pyrimidines tyrosine kinase inhibitors |
ATE314370T1 (de) | 2002-01-22 | 2006-01-15 | Warner Lambert Co | 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one |
CA2555724A1 (en) | 2004-02-18 | 2005-09-09 | Warner-Lambert Company Llc | 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
WO2005105097A2 (en) | 2004-04-28 | 2005-11-10 | Gpc Biotech Ag | Pyridopyrimidines for treating inflammatory and other diseases |
US20060142312A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
GB0428475D0 (en) * | 2004-12-30 | 2005-02-02 | 4 Aza Bioscience Nv | Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
MX2007007901A (es) * | 2004-12-30 | 2007-11-07 | 4 Aza Ip Nv | Pirido-(3,2-d)pirimidinas y composiciones farmaceuticas utiles para tratamiento medico. |
US8232278B2 (en) * | 2005-06-24 | 2012-07-31 | Gilead Sciences, Inc. | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C |
CA2624965A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of pi3k.alpha. |
BRPI0617159B8 (pt) * | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo |
WO2008016682A2 (en) | 2006-08-02 | 2008-02-07 | Temple University - Of The Commonwealth System Of Higher Education | Aryl vinyl sulfides, sulfones, sulfoxides and sulfonamides, derivatives thereof and therapeutic uses thereof |
EP2084159A1 (en) | 2006-10-16 | 2009-08-05 | GPC Biotech Inc. | Pyrido ý2, 3-d¨pyrimidines and their use as kinase inhibitors |
WO2008150260A1 (en) | 2007-06-06 | 2008-12-11 | Gpc Biotech, Inc. | 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents |
CA2784749C (en) | 2009-12-18 | 2017-12-12 | E. Premkumar Reddy | Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof |
CA2807498C (en) * | 2010-08-05 | 2017-02-07 | Temple University-Of The Commonwealth System Of Higher Education | 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof |
-
2011
- 2011-07-21 CA CA2807498A patent/CA2807498C/en active Active
- 2011-07-21 CN CN201180038325.3A patent/CN103200822B/zh active Active
- 2011-07-21 NZ NZ606281A patent/NZ606281A/en unknown
- 2011-07-21 WO PCT/US2011/044807 patent/WO2012018540A1/en active Search and Examination
- 2011-07-21 EA EA201390199A patent/EA022527B1/ru not_active IP Right Cessation
- 2011-07-21 AU AU2011286282A patent/AU2011286282B2/en active Active
- 2011-07-21 US US13/813,023 patent/US8987267B2/en active Active
- 2011-07-21 JP JP2013523185A patent/JP5512894B2/ja active Active
- 2011-07-21 ES ES11815012.7T patent/ES2525866T3/es active Active
- 2011-07-21 KR KR1020137004979A patent/KR101434841B1/ko active IP Right Grant
- 2011-07-21 PT PT118150127T patent/PT2600719E/pt unknown
- 2011-07-21 DK DK11815012.7T patent/DK2600719T3/da active
- 2011-07-21 EP EP11815012.7A patent/EP2600719B1/en active Active
- 2011-07-21 PL PL11815012T patent/PL2600719T3/pl unknown
- 2011-07-21 MX MX2013001427A patent/MX2013001427A/es active IP Right Grant
- 2011-07-21 BR BR112013002375-9A patent/BR112013002375B1/pt active IP Right Grant
-
2013
- 2013-02-03 IL IL224555A patent/IL224555A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
AU2011286282A1 (en) | 2013-02-14 |
WO2012018540A1 (en) | 2012-02-09 |
BR112013002375B1 (pt) | 2020-05-12 |
EA022527B1 (ru) | 2016-01-29 |
CA2807498C (en) | 2017-02-07 |
NZ606281A (en) | 2014-09-26 |
PT2600719E (pt) | 2014-12-22 |
EP2600719A1 (en) | 2013-06-12 |
CN103200822A (zh) | 2013-07-10 |
ES2525866T3 (es) | 2014-12-30 |
EP2600719B1 (en) | 2014-10-08 |
KR101434841B1 (ko) | 2014-08-29 |
CA2807498A1 (en) | 2012-02-09 |
EA201390199A1 (ru) | 2013-07-30 |
EP2600719A4 (en) | 2014-01-01 |
DK2600719T3 (da) | 2014-12-15 |
US20130131058A1 (en) | 2013-05-23 |
US8987267B2 (en) | 2015-03-24 |
CN103200822B (zh) | 2014-12-24 |
IL224555A (en) | 2016-03-31 |
MX2013001427A (es) | 2013-06-13 |
KR20130098314A (ko) | 2013-09-04 |
JP2013538196A (ja) | 2013-10-10 |
AU2011286282B2 (en) | 2014-08-21 |
PL2600719T3 (pl) | 2015-03-31 |
JP5512894B2 (ja) | 2014-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013002375A2 (pt) | composto, composição farmacêutica, métodos de tratar um indivíduo para um distúrbio proliferativo de induzir a apoptose das células cancerígenas, e de inibir a atividade de cinase em um mamífero, e, processo de preparação de composto | |
BR112014010576B8 (pt) | compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos | |
DOP2014000204A (es) | Compuestos de heterociclilo como inhibidores de mek | |
CR20150045A (es) | Inhibidores de hepatitis c | |
BR112014005226A2 (pt) | derivados de benzonitrila como inibidores de cinase | |
BR112014018959A8 (pt) | Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer | |
PE20210667A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
BR112013021537A2 (pt) | derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase | |
UY33440A (es) | ?compuestos pirimidinílicos para uso como inhibidores de atr?. | |
CR20130550A (es) | Ciclopropilaminas como inhibidores de desmetilasa 1 específica de lisina | |
BR112014002675A2 (pt) | "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição" | |
CL2012003110A1 (es) | Compuestos derivados de n-[(2-oxo-1,2-dihidro-3-piridinil)metil]-1h-indol-4-carboxamida, inhibidores de ezh2; composicion farmaceutica que los contiene; utiles en el tratamiento del cancer seleccionado del grupo que consiste de cerebro (gliomas) glioblastomas, leucemias y linfomas, y trastornos mediados por la inhibicion del ezh2. | |
BR112013024122A2 (pt) | compostos de benzoxazepina seletivos para p110 delta pi3k e métodos de uso | |
BR112017004741A2 (pt) | compostos e composições como inibidores da raf quinase | |
BR112014010420A2 (pt) | inibidores de pak para o tratamento de distúrbios proliferativos celulares | |
BR112014016163A8 (pt) | piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp | |
BR112014007622A2 (pt) | inibidores de flt3 cinase macrocíclicos | |
DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
EA201270752A1 (ru) | Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью | |
BR112013029999A2 (pt) | derivados de tiazol | |
CO7350640A2 (es) | Compuestos diméricos | |
BR112015000386A2 (pt) | derivados de azaindol os quais agem como inibidores de pi3k | |
BR112013004662B8 (pt) | Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica | |
BR112014017985A8 (pt) | Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer | |
BR112013017362A2 (pt) | composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/07/2011, OBSERVADAS AS CONDICOES LEGAIS. |